01 / Decision point
Company state
Founder-led, early-stage, and pre-revenue unless supported by signed documentary evidence.
Investor overview / Accountable intelligence infrastructure
One commercial wedge. Seven retained programs.
Planckchron is building accountable intelligence infrastructure for consequential workflows. HERA Nexus is the near-term commercial entry point; Athena, Aetherion Core, BioForge + GenovaX, Helios Autonomy, EchoNet, and PX-Phantom remain independently gated programs within the portfolio.
HERA NexusNear-term commercial wedge
90 daysCustomer, product, security, and pilot evidence targets
Seven programsEvery program has an evidence and capital gate
Pre-revenueNo established revenue represented without evidence
Investor decision brief / September 2026
The company in one diligence-ready view.
02 / Decision point
Category
Accountable intelligence infrastructure for consequential workflows.
03 / Decision point
Commercial wedge
HERA Nexus: a human-supervised intelligence layer for consequential, evidence-heavy workflows.
04 / Decision point
Reference workflow
Technical Evidence Review & Approval
05 / Decision point
Portfolio model
Seven retained programs governed by three operating horizons and explicit evidence gates.
06 / Decision point
Public evidence boundary
No undisclosed revenue, customer, benchmark, patent, certification, partnership, staffing, or financing result is represented as validated.
This public brief is informational only. It is not an offer to sell securities, a solicitation, a projection of guaranteed outcomes, or a substitute for legal, financial, technical, commercial, capitalization, intellectual-property, regulatory, and conflict diligence.
Investment thesis
The portfolio is broad. The operating model is concentrated.
One operating architecture, one near-term commercial wedge, and six milestone-gated proving grounds.
01
A category with a focused entry point
Planckchron is building accountable intelligence infrastructure for consequential workflows. HERA Nexus is the near-term commercial wedge; the remaining programs are milestone-gated proving grounds for a shared evidence, authority, governance, and human-intervention architecture.
02
Consequence creates demand for accountability
Organizations operating regulated, evidence-heavy, or safety-sensitive workflows need traceable decisions, explicit permissions, intervention boundaries, and accountable human ownership—not another unbounded chat layer.
03
Capital follows evidence
Programs advance only when a technical, customer, governance, or economic uncertainty is materially reduced. The portfolio remains intact, but capital concentration is earned rather than assumed.
Portfolio sequencing
Every product stays. Every dollar has an order.
Program maturity and capital priority are not the same thing. HERA receives near-term commercial concentration; adjacent and long-horizon programs advance through explicit evidence gates.
01 / Commercial wedgeDevelopment
HERA Nexus
Artificial intelligence. Validate Technical Evidence Review & Approval as one human-supervised workflow with a qualified design partner and measurable operating outcomes.
Next gate: Controlled external evaluation, security artifacts, published evidence records, and a documented path to a paid pilot.
Review program
02 / Long-horizon R&DDevelopment
Athena
Clinical decision support. Build evidence-linked chart synthesis and review summaries that keep a named clinician accountable for every output, ahead of any clinical evaluation.
Next gate: Retrospective de-identified dataset, a documented review protocol, clinician-in-the-loop error analysis, and an independent methodology review.
Review program
03 / Adjacent validationDevelopment
EchoNet
Resilient communications. Demonstrate bounded coordination and graceful degradation in a controlled network environment.
Next gate: Documented test method, network conditions, repeatable results, and failure analysis.
Review program
04 / Adjacent validationDevelopment
Helios Autonomy
Autonomous systems. Test accountable perception, planning, escalation, and human intervention boundaries in simulation.
Next gate: Scenario suite, intervention criteria, recorded decisions, and independent technical review.
Review program
05 / Long-horizon R&DDevelopment
Aetherion Core
Emerging compute. Define and test the most consequential assumptions in the post-silicon and hybrid compute architecture.
Next gate: Published architecture note, simulation method, reproducible model, and clearly labeled limitations.
Review program
06 / Long-horizon R&DDevelopment
BioForge + GenovaX
Biotechnology. Develop evidence-aware research workflows and identify one bounded biotechnology use case for external review.
Next gate: Defined research question, responsible-review process, reproducible workflow, and qualified domain partner.
Review program
07 / Long-horizon R&DDevelopment
PX-Phantom
Aerospace systems. Convert the aerospace thesis into a simulation-led research program with explicit engineering constraints.
Next gate: Requirements baseline, simulation assumptions, engineering review, and dated test plan.
Review program
Commercial entry point
Start where evidence, authority, and AI collide.
Engineering, R&D, operations, and compliance teams in regulated or safety-sensitive organizations that require AI assistance without losing source traceability, human authority, reviewable decisions, or accountable action.
01
Why now?
AI adoption is moving faster than institutional mechanisms for review, evidence, authority, and accountability.
02
Why this company model?
Management is concentrating the near-term product and validation loop around HERA rather than staffing seven independent businesses. Team expansion is tied to milestones and external evidence.
03
What is the first workflow?
Technical Evidence Review & Approval
04
What must be proven next?
A bounded HERA workflow must demonstrate measurable operating value, retained external use, and a credible path to paid pilot activity.
Near-term execution / 90-day scorecard
Before the larger story, prove one commercial loop.
These are management targets, not represented achievements. Each target must create a dated evidence artifact that either unlocks the next gate or forces a change in strategy.
| Dimension | 90-day target | Evidence required |
|---|---|---|
| Customer discovery | >=30 qualified interviews | Interview log, scoring matrix, pain patterns, workflow ownership, buying authority, and willingness-to-pilot record. |
| Design partners | >=3 controlled evaluations | Qualified partner record, agreed workflow, baseline conditions, data boundary, and pre-defined success criteria. |
| Paid-pilot path | >=1 documented conversion path | Pilot intent, commercial next-step documentation, or executed paid pilot when available. |
| Primary workflow | 1 frozen measurable workflow | Workflow specification, accountable owner, baseline, prohibited actions, and acceptance criteria. |
| Evidence coverage | 100% of consequential outputs traceable | Source linkage, assumption state, transformations, confidence boundary, and review status in the prototype. |
| Human authority | 100% of consequential actions have approval/override paths | Authority graph, role permissions, escalation path, intervention control, and disposition record. |
| Security readiness | Core security artifacts complete | Threat model, data-flow diagram, access-control model, privacy boundary, retention rules, and incident-response outline. |
| Product focus | >=80% of near-term product/engineering effort on HERA | Roadmap, resource allocation, and weekly operating review. |
| Claims discipline | 0 unsupported public claims | Claim register, evidence-registry review, and explicit separation of targets from achieved results. |
18-month operating plan
Capital buys decisions—not optics.
The plan moves from a defined customer problem to a bounded prototype, controlled external evaluation, and paid-pilot conversion path.
0–3 months
Freeze the HERA v1 problem definition, customer profile, Technical Evidence Review & Approval workflow, technical architecture, security boundary, and measurement plan.
Proceed only with a named accountable workflow and an external design-partner signal.4–6 months
Deliver a bounded HERA prototype with evidence capture, Decision Packets, human approval, intervention controls, role permissions, and audit history.
Proceed only if the prototype reduces a measurable workflow failure or operating burden in controlled evaluation.7–12 months
Run controlled design-partner evaluations and publish dated evidence records for the primary workflow when disclosure is permitted.
Proceed only with retained use, credible user pull, and a defined path to a paid pilot.13–18 months
Convert validated use into paid pilot activity while advancing one EchoNet or Helios adjacent validation program only if HERA evidence supports expansion.
Scale headcount and capital only when technical evidence, governance, and economics support expansion.Illustrative use of proceeds
Concentrate capital where uncertainty can be reduced.
Final round size, security, ownership impact, runway assumptions, and line-item budget must reconcile to the capitalization table and approved operating plan during qualified diligence.
| Allocation | Priority | Required output |
|---|---|---|
| 45% | Core product and engineering | HERA prototype, evidence graph, authority graph, Decision Packets, security architecture, and production-quality technical foundation. |
| 20% | Design partnerships and validation | External workflow definition, controlled evaluations, user evidence, and paid-pilot conversion path. |
| 15% | Technical talent and domain review | Full-time engineering capacity plus qualified independent review for high-consequence technical claims. |
| 10% | Security, governance, and compliance | Access controls, privacy practices, review boundaries, threat modeling, incident readiness, and diligence-ready records. |
| 10% | Focused operations and runway | Legal, finance, recruiting, program management, and operating cadence tied to approved milestones. |
Qualified diligence
A serious conversation starts with documents.
Qualified investors should test ownership, technical evidence, operating assumptions, commercial signals, intellectual property, disclosed relationships, conflicts, and legal readiness.
01
Corporate formation, capitalization, ownership, and material agreements
02
90-day scorecard plus 18-month operating plan, milestone budget, hiring plan, runway, and financing structure
03
HERA product architecture, security model, threat model, technical assumptions, and evidence records
04
Customer-discovery log, design-partner pipeline, pilot criteria, baseline measures, and commercial model
05
Intellectual-property inventory, contributor assignments, and third-party dependency review
06
Advisor appointment documentation, role scope, disclosure consent, and conflict review
Diligence access
Qualify the investor before opening the data room.
The public site provides the thesis and evidence boundaries. Non-public materials are released selectively after investment-fit, identity, conflict, confidentiality, and legal review.
Access sequence
What happens after submission
- 01 — Qualification. Confirm firm, role, mandate, strategic fit, and likely financing pathway.
- 02 — Conflict and confidentiality. Determine whether an NDA or other access terms are appropriate.
- 03 — Scoped release. Share only materials relevant to the approved diligence stage.
- 04 — Management review. Resolve technical, commercial, capitalization, governance, and risk questions.
Qualified access request
Request an investor briefing and diligence review.
Do not submit confidential, proprietary, export-controlled, medical, classified, or material non-public information through this form.
Material uncertainty
The risks are part of the investment case.
This public summary is not an offer to sell securities and is not a substitute for complete legal, technical, financial, capitalization, commercial, intellectual-property, conflict, and regulatory diligence.
01
Technical
The architecture or individual programs may not achieve intended performance, reliability, integration, or safety.
02
Focus
Management must protect the HERA commercial wedge from long-horizon distraction and apply explicit capital gates.
03
Commercial
Design-partner interest may not convert into paid pilots, repeatable demand, or durable revenue.
04
Team
Planckchron must recruit full-time engineering, product, security, and domain leadership appropriate to each approved milestone.
05
Capital
Frontier programs may require more financing than anticipated, creating dilution and sequencing risk.
06
Regulatory
AI, biotechnology, autonomy, aerospace, privacy, and security requirements may change across jurisdictions.
Investor briefing
Evaluate the company as it is—and the milestones disciplined capital can unlock.
Review HERA, the 90-day execution scorecard, and the evidence registry first; then request scoped access for capitalization, budget, technical, commercial, intellectual-property, governance, and risk diligence.
